scispace - formally typeset
K

Klaas Nico Faber

Researcher at University Medical Center Groningen

Publications -  176
Citations -  6452

Klaas Nico Faber is an academic researcher from University Medical Center Groningen. The author has contributed to research in topics: Medicine & Inflammatory bowel disease. The author has an hindex of 35, co-authored 134 publications receiving 4286 citations. Previous affiliations of Klaas Nico Faber include Erasmus University Rotterdam & University of Groningen.

Papers
More filters
Journal ArticleDOI

Short Chain Fatty Acids (SCFAs)-Mediated Gut Epithelial and Immune Regulation and Its Relevance for Inflammatory Bowel Diseases.

TL;DR: An overview of microbial SCFAs production and their effects on the intestinal mucosa with specific emphasis on their relevance for Inflammatory Bowel Diseases is presented and the therapeutic potential ofSCFAs for IBD is discussed.
Journal ArticleDOI

Farnesoid X receptor and bile salts are involved in transcriptional regulation of the gene encoding the human bile salt export pump

TL;DR: Results show thatFXR is required for the bile salt–dependent transcriptional control of the human ABCB11 gene and that the cellular amount of FXR is critical for the level of activation ofABCB11 transcription.
Journal ArticleDOI

Drug transport proteins in the liver

TL;DR: Together with drug metabolising enzymes, transmembrane transporters are important determinants of drug metabolism and drug clearance by the liver and are subject to genetic polymorphism in the encoding genes as well as in these transcription factors.
Journal ArticleDOI

LPS-induced downregulation of MRP2 and BSEP in human liver is due to a posttranscriptional process

TL;DR: It is shown that posttranscriptional mechanisms play a more prominent role in LPS-induced regulation of human MRP2 and BSEP compared with the rat transporter proteins.
Journal ArticleDOI

Effects of active and passive smoking on disease course of Crohn's disease and ulcerative colitis

TL;DR: Active smoking is a risk factor for CD, but does not affect the outcome; passive smoking is detrimental for the outcome of CD patients, and the data suggest that passivesmoking is a novel risk factors for CD.